CLINICAL_TRIALS
trial_result
· 2020-10-08
Clinical Trial Update: Selinexor (KPT-330) in Older Patients With Relapsed AML [Phase 2]
Summary
Phase 2 clinical trial update for selinexor (KPT-330) in older patients with relapsed acute myeloid leukemia (AML) has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Karyopharm Therapeutics Inc | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: COMPLETED | Results posted: 2020-10-08